



Adult CIRB - Early Phase Emphasis Meeting Agenda

March 3, 2026

I New Study - Initial Review

10713, A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma (Version Date 01/07/26)

II New Study - Initial Review

10760, A Phase I Study of Glofitamab with Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma (Version Date 01/26/26)

III Continuing Review

10466, A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer (Version Date 03/03/25)

IV Continuing Review

10525, A Phase 1b Trial of ZEN003694 (ZEN-3694) with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer (Version Date 09/17/25)

V Continuing Review

NRG-GY031, A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer (Version Date 11/03/25)

C>I>R>B

FOR THE NATIONAL CANCER INSTITUTE